{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:24:20Z","timestamp":1790130260043,"version":"4.0.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"University of Queensland Summer Research"}],"content-domain":{"domain":["clinicalkey.jp","schres-journal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.schres.2015.04.028","type":"journal-article","created":{"date-parts":[[2015,5,18]],"date-time":"2015-05-18T10:04:27Z","timestamp":1431943467000},"page":"178-186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["A systematic review and meta-analysis of the effect of depot antipsychotic frequency on compliance and outcome"],"prefix":"10.1016","volume":"166","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4021-2924","authenticated-orcid":false,"given":"Steve","family":"Kisely","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Sawyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2072-9216","authenticated-orcid":false,"given":"Dan","family":"Siskind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2015.04.028_bb0005","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1192\/bjp.179.4.290","article-title":"Systematic meta-review of depot antipsychotic drugs for people with schizophrenia","volume":"179","author":"Adams","year":"2001","journal-title":"Br. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2015.04.028_bb0010","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.biopsych.2009.08.040","article-title":"Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs","volume":"67","author":"Andreasen","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2015.04.028_bb0015","first-page":"111","article-title":"Long-term safety and tolerability of once-monthly aripiprazole intramuscular depot for maintenance treatment in schizophrenia","volume":"15","author":"Baker","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2015.04.028_bb0020","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/2046-4053-1-2","article-title":"The nuts and bolts of PROSPERO: an international prospective register of systematic reviews","volume":"1","author":"Booth","year":"2012","journal-title":"Syst. Rev."},{"issue":"11","key":"10.1016\/j.schres.2015.04.028_bb0025","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1185\/03007995.2013.835715","article-title":"Real-world use patterns of olanzapine long-acting injection in the United States: comparison to the recommended dosing strategy","volume":"29","author":"Case","year":"2013","journal-title":"Curr. Med. Res. Opin."},{"issue":"3","key":"10.1016\/j.schres.2015.04.028_bb0030","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1176\/ajp.139.3.312","article-title":"Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect","volume":"139","author":"Chouinard","year":"1982","journal-title":"Am. J. Psychiatry"},{"issue":"11","key":"10.1016\/j.schres.2015.04.028_bb0035","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1517\/14656566.2012.686169","article-title":"A review of olanzapine pamoate","volume":"13","author":"Chue","year":"2012","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.schres.2015.04.028_bb0040","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/1472-6963-11-236","article-title":"The cost associated with administering risperidone long-acting injections in the Australian community","volume":"11","author":"Dalton","year":"2011","journal-title":"BMC Health Serv. Res."},{"key":"10.1016\/j.schres.2015.04.028_bb0045","first-page":"CD000307","article-title":"Depot fluphenazine decanoate and enanthate for schizophrenia","volume":"1","author":"David","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.schres.2015.04.028_bb0050","first-page":"Cd007906","article-title":"Intensive case management for severe mental illness","volume":"10","author":"Dieterich","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"issue":"7","key":"10.1016\/j.schres.2015.04.028_bb0055","doi-asserted-by":"crossref","first-page":"A560","DOI":"10.1016\/j.jval.2011.08.1666","article-title":"Comparing the effectiveness of paliperidone palmitate versus olanzapine pamoate for relapse prevention in schizophrenia: post HOC indirect analysis using published placebo-controlled studies","volume":"14","author":"Einarson","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.schres.2015.04.028_bb0060","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1192\/bjp.195.52.s29","article-title":"Second-generation antipsychotic long-acting injections: systematic review","volume":"52","author":"Fleischhacker","year":"2009","journal-title":"Br. J. Psychiatry Suppl."},{"issue":"10","key":"10.1016\/j.schres.2015.04.028_bb0065","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.4088\/JCP.v64n1017","article-title":"Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic","volume":"64","author":"Fleischhacker","year":"2003","journal-title":"J. Clin. Psychiatry"},{"issue":"Suppl. 16","key":"10.1016\/j.schres.2015.04.028_bb0075","first-page":"10","article-title":"Factors influencing compliance in schizophrenia patients","volume":"64","author":"Fleischhacker","year":"2003","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2015.04.028_bb0070","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1017\/S1461145711001076","article-title":"A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia","volume":"15","author":"Fleischhacker","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2015.04.028_bb0080","doi-asserted-by":"crossref","first-page":"S472","DOI":"10.1016\/S0924-977X(10)70696-9","article-title":"Risperidone depot versus zuclopenthixol depot for schizophrenia and schizophrenia-like psychoses: real world outcomes","volume":"20","author":"Fricchione Parise","year":"2010","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2015.04.028_bb0085","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1744-859X-6-3","article-title":"Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval","volume":"6","author":"Gharabawi","year":"2007","journal-title":"Ann. Gen. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2015.04.028_bb0090","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1447-0349.2009.00649.x","article-title":"Enhancing medication adherence in people with schizophrenia: an international programme of research","volume":"19","author":"Gray","year":"2010","journal-title":"Int. J. Ment. Health Nurs."},{"issue":"3","key":"10.1016\/j.schres.2015.04.028_bb0095","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00406-014-0558-9","article-title":"S3 guideline on psychosocial therapies in severe mental illness: evidence and recommendations","volume":"265","author":"Guhne","year":"2014","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.schres.2015.04.028_bb0100","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2008"},{"issue":"2","key":"10.1016\/j.schres.2015.04.028_bb0105","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1176\/ps.2010.61.2.189","article-title":"Nonadherence to medication four years after a first episode of psychosis and associated risk factors","volume":"61","author":"Hill","year":"2010","journal-title":"Psychiatr. Serv."},{"issue":"2","key":"10.1016\/j.schres.2015.04.028_bb0110","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1176\/appi.ajp.2009.07081221","article-title":"Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia","volume":"167","author":"Kane","year":"2010","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2015.04.028_bb0115","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1192\/bjp.bp.105.017020","article-title":"Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study","volume":"191","author":"Keks","year":"2007","journal-title":"Br. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2015.04.028_bb0120","doi-asserted-by":"crossref","first-page":"E50","DOI":"10.1503\/cmaj.121077","article-title":"Reducing all-cause mortality among patients with psychiatric disorders: a population-based study","volume":"185","author":"Kisely","year":"2013","journal-title":"CMAJ"},{"issue":"3","key":"10.1016\/j.schres.2015.04.028_bb0130","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1055\/s-2007-1017373","article-title":"Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months' treatment for relapse prevention","volume":"18","author":"Kissling","year":"1985","journal-title":"Pharmacopsychiatry"},{"issue":"5 Suppl.","key":"10.1016\/j.schres.2015.04.028_bb0125","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/0269881105056514","article-title":"Direct transition to long-acting risperidone \u2014 analysis of long-term efficacy","volume":"19","author":"Kissling","year":"2005","journal-title":"J. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.schres.2015.04.028_bb0135","doi-asserted-by":"crossref","first-page":"790","DOI":"10.4088\/JCP.v69n0512","article-title":"An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia","volume":"69","author":"Lauriello","year":"2008","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2015.04.028_bb0140","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.schres.2010.11.020","article-title":"Oral versus depot antipsychotic drugs for schizophrenia\u2014a critical systematic review and meta-analysis of randomised long-term trials","volume":"127","author":"Leucht","year":"2011","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.schres.2015.04.028_bb0145","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.pnpbp.2011.02.001","article-title":"A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia","volume":"35","author":"Li","year":"2011","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"12","key":"10.1016\/j.schres.2015.04.028_bb0150","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.schres.2015.04.028_bb0155","first-page":"CD001089","article-title":"Assertive community treatment for people with severe mental disorders","volume":"2","author":"Marshall","year":"2000","journal-title":"Cochrane Database Syst. Rev."},{"issue":"19","key":"10.1016\/j.schres.2015.04.028_bb0160","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1001\/jama.2014.4310","article-title":"Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial","volume":"311","author":"McEvoy","year":"2014","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.schres.2015.04.028_bb0165","doi-asserted-by":"crossref","first-page":"844","DOI":"10.3111\/13696998.2012.681531","article-title":"Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden","volume":"15","author":"Mehnert","year":"2012","journal-title":"J. Med. Econ."},{"issue":"4","key":"10.1016\/j.schres.2015.04.028_bb0170","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.schres.2015.04.028_bb0175","first-page":"CD008296","article-title":"Paliperidone palmitate for schizophrenia","volume":"6","author":"Nussbaum","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.schres.2015.04.028_bb0180","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.pnpbp.2010.11.008","article-title":"A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia","volume":"35","author":"Pandina","year":"2011","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2015.04.028_bb0185","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1192\/apt.11.3.203","article-title":"Why aren't depot antipsychotics prescribed more often and what can be done about it?","volume":"11","author":"Patel","year":"2005","journal-title":"Adv. Psychiatr. Treat."},{"key":"10.1016\/j.schres.2015.04.028_bb0190","first-page":"CD001717","article-title":"Depot perphenazine decanoate and enanthate for schizophrenia","volume":"2","author":"Quraishi","year":"2000","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.schres.2015.04.028_bb0195","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1176\/appi.ajp.2011.10081224","article-title":"A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia","volume":"168","author":"Tiihonen","year":"2011","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2015.04.028_bb0200","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1185\/03007995.2012.657300","article-title":"Effects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophrenia","volume":"28","author":"Witte","year":"2012","journal-title":"Curr. Med. Res. Opin."},{"issue":"5","key":"10.1016\/j.schres.2015.04.028_bb0205","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40258-013-0050-0","article-title":"Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany","volume":"11","author":"Zeidler","year":"2013","journal-title":"Appl. Health Econ. Health Policy"},{"issue":"10","key":"10.1016\/j.schres.2015.04.028_bb0210","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1176\/appi.ajp.159.10.1653","article-title":"Interventions to improve medication adherence in schizophrenia","volume":"159","author":"Zygmunt","year":"2002","journal-title":"Am. J. Psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996415002236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996415002236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T10:25:14Z","timestamp":1537611914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996415002236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":42,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0920996415002236"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2015.04.028","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review and meta-analysis of the effect of depot antipsychotic frequency on compliance and outcome","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2015.04.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}